CN104547357B - A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof - Google Patents
A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104547357B CN104547357B CN201510069987.7A CN201510069987A CN104547357B CN 104547357 B CN104547357 B CN 104547357B CN 201510069987 A CN201510069987 A CN 201510069987A CN 104547357 B CN104547357 B CN 104547357B
- Authority
- CN
- China
- Prior art keywords
- tablet
- active ingredient
- allergic rhinitis
- preparation
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of tablet formulations and preparation method thereof for treating allergic rhinitis, the tablet is made of 70% Chinese medical concrete active ingredient and 30% excipient, wherein the active ingredient is radix scutellariae, Radix Astragali, schizonepeta, the root of Dahurain angelica, the achene of Siberian cocklebur, cassia twig, Shi Cangpu, Rhizoma Atractylodis Macrocephalae and the windproof water extract for raw material of equivalent, and excipient includes filler, disintegrant, lubricant and coating auxiliary material.The specification of tablet is 0.6g, 5 oral every time.Technical solution provided by the invention can get the effect for the treatment of allergic rhinitis again while reducing genotoxic potential, make this Chinese medicine compound prescription not only extensive but also safe clinic of being applied to.
Description
Technical field
The present invention relates to a kind of compound Chinese medicinal preparations, and in particular to a kind of compound preparation and its system for treating allergic rhinitis
Preparation Method.
Background technology
Allergic rhinitis are a kind of diseases that ear-nose-throat department is common, and the whole world has 30% people to be influenced by this disease.Clinically often
Be main performance with rhiocnesmus, sneezing, watery nasal discharge, nasal obstruction, at the same with conjunctival congestion, pharyngeal discomfort, even induce asthma, and
It may cause anosmia, and there is recurrent exerbation, the characteristics of should not effecting a radical cure.Chinese medicine, which treats allergic rhinitis, has raising antibody
Immune function reduces the characteristics of body hypersensitive state.Existed by the pungent a kind of reed mentioned in ancient books granule of the Chinese patent drug prepared based on pungent a kind of reed mentioned in ancient books side, xinqin tablet
Clinical treatment allergic rhinitis have a better effect, but contain Asarum medicinal materials in pungent a kind of reed mentioned in ancient books side, contain aristolochic acid in asarum,
Long-term use can lead to renal toxicity.From after aristolochic acid event, related rule are made in countries in the world to the medicinal material containing aristolochic acid
It is fixed.For this reason, it may be necessary to which providing a kind of can improve curative effect of medication again and can reduce the technical solution of its toxic side effect.
Invention content
Allergic rhinitis safely and effectively compound Chinese medicinal preparation and its preparation side are treated the object of the present invention is to provide a kind of
Method.
The purpose of the present invention is what is be achieved through the following technical solutions：
The tablet for the treatment of allergic rhinitis provided by the invention, by 70% active ingredient of weight percent meter and 30%
Excipient composition；The active ingredient is radix scutellariae, Radix Astragali, schizonepeta, the root of Dahurain angelica, the achene of Siberian cocklebur, cassia twig, grass-leaved sweetflag, the Rhizoma Atractylodis Macrocephalae of equivalent
With the water extract of windproof nine tastes medicinal material；The excipient includes the filler medically received, disintegrant, adhesive, helps stream
Agent and coating auxiliary material.
In first optimal technical scheme of the tablet provided by the invention, the filler is microcrystalline cellulose, starch
One or more of with pregelatinized starch；The disintegrant is sodium carboxymethyl starch, crospovidone and low-substituted hydroxypropyl first
One or more of base cellulose；Described adhesive is in sodium carboxymethylcellulose, povidone and hydroxypropyl methyl cellulose
One or more；The glidant is one or more of magnesium stearate, superfine silica gel powder and talcum powder；The coating auxiliary material
For hydroxypropyl methyl cellulose, Utech E100, Utech EPO andOne or more of amb.
In second optimal technical scheme of the tablet provided by the invention, the filler account for sheet weight 10~
25%, the disintegrant accounts for the 4~8% of sheet weight, and described adhesive accounts for the 2~6% of sheet weight, and the glidant accounts for sheet weight
0.5~1%.
In the third optimal technical scheme of the tablet provided by the invention, the filler is the 20% of sheet weight, institute
6% that disintegrant is sheet weight is stated, described adhesive is the 3% of sheet weight, and the glidant is the 1% of sheet weight.
It is provided by the present invention treatment allergic rhinitis tablet preparation method be：By the extract powder of active ingredient and filling
Agent, disintegrant, adhesive mixed pelletization are added glidant tabletting, then are coated, and obtain the composite tablet.
In first optimal technical scheme of the method for preparing tablet thereof, the preparation method of the active ingredient extract powder is：
Equivalent medicinal material is taken, 10 times of amount water are added, decoct twice, 1.5 hours for the first time, second 1 hour, being concentrated to give relative density was
1.1~1.2 active ingredient water extract, it is dry, obtain the active ingredient extract powder.
In second optimal technical scheme of the method for preparing tablet thereof, the drying mode of the active ingredient water extract is
Constant pressure and dry, be dried under reduced pressure and be spray-dried in one kind.
In the third optimal technical scheme of the method for preparing tablet thereof, the drying means of the active ingredient water extract：
Constant pressure and dry at 60~80 DEG C；It is dried under reduced pressure at a temperature of 5~8Kpa pressure and 50~60 DEG C；The inlet air temperature of spray drying is
120~140 DEG C, leaving air temp is 70~80 DEG C.
To show that therapeutic effect of the compound Chinese medicinal preparation of the present invention to allergic rhinitis, the present invention use said extracted technique
Extract powder is obtained, its effect to cavy allergic rhinitis is studied.It prepares pungent a kind of reed mentioned in ancient books side with identical technique simultaneously to compare, mainly
Process is as follows：
● experiment reagent, instrument and animal
Toluene-2,4-diisocyanate, 4- diisocyanate (TDI, sigma, lot number：SHBD198V)；Guinea Pig Histamine kit (the excellent that in Wuhan
It is raw, lot number：L140312255)；Loratadine (Shanghai Schering Plough pharmaceutical Co. Ltd, lot number：11JRXF1039)；Methylol
Sodium cellulosate (CMC-Na, Sinopharm Chemical Reagent Co., Ltd., lot number：F20060125)；Paraformaldehyde (recover by Tianjin
Fine chemistry industry research institute, lot number：50116)；Cavy (300 ± 50g), male, 50, production licence number：Animal feeding is in clear
Clean grade, animal feeding credit number：Cavy SYXK (Chongqing) 2012-0011；
● experimental method and result
1) preparation of extract powder
According to the ratio of each medicine in the present invention, each medicine 50g is weighed respectively, and the water that 10 times of amounts are added decocts secondary, first time
1.5h, second of 1h, decocting liquid filtration, filtrate merge, and are concentrated into certain volume, are dried in vacuo, obtain dry extract, be placed in drier
In it is spare.Same method prepares pungent a kind of reed mentioned in ancient books prescription extracts.
2) foundation of cavy allergic rhinitis model
With reference to the method for building up of animal pathological model in Li Yikui, cavy 35 is bought, adaptability is raised 3 days.Except normal
Outside, remaining animal instills 10%TDI olive oil solutions to group (7) per Nikkei bilateral nasal cavity, per side 5ul, one time a day, continuous 7
Day, the normal daily olive oil for instilling same volume of group.After the 7th day collunarium, observation cavy nose office in 15min after excitation
Portion's symptom, and record cavy and grab nose, sneeze and the number of watery nasal discharge and severity, and score and (grab nose：Light nose of grabbing is for 1~2 time
1 point, it is 2 points acutely to grab nose surrounding；Sneeze：1~3 is 1 point, and 4~10 are 2 points, and 11 or more are 3 points；Runny nose：Before flowing to
Nostril is 1 point, is 2 points more than prenaris, it is 3 points that tears stream, which is had one's face covered with).Appraisal result is more than 5 points of persons, modeling success.
3) cavy grouping and administration
Take the successful cavy of modeling 40, be randomly divided into model group, Loratadine group (1mg/kg, clinical equivalent dosage),
Of the present invention group (1.8g/kg, 3 times of clinical equivalent dosage) and pungent a kind of reed mentioned in ancient books side's group (2.1g/kg, 3 times of clinical equivalent dosage).Each group
Cavy gastric infusion (1ml/200g), 1 time a day, continuous 14 days, model group and blank group gave isometric 0.5%CMC-
Na.During administration, TDI is changed to 1h collunariums upon administration, the next day stimulate, to reinforce attacking.
4) guinea-pig nasal semiograhy
After gastric infusion, the number for grabbing nose, sneeze and runny nose after TDI is stimulated in 15min is observed and recorded, before administration
Comparing for nose and sneeze number is grabbed, the improvement situation of its cavy nasal symptom is observed.Each cavy nose symptom treatment fore-and-aft observing
Method is commented using blind.
As shown in Figure 1：Model group grabs nose and the equal conspicuousness of sneezing number increases, show allergia compared with blank group
Rhinitis models modeling success；Each administration group is compared with model group, and pungent a kind of reed mentioned in ancient books side's group and of the present invention group are for grabbing nose number and sneeze time
Number is substantially reduced；Compared with pungent a kind of reed mentioned in ancient books side, the of the present invention group of advantage with conspicuousness in terms of improving cavy and grabbing nose number.
5) in guinea pig serum histamine detection
After gastric infusion, by 10% chloral hydrate anesthesia of cavy, femoral artery takes blood.Stand 2h, 3000rpm from
Heart 10min, takes serum, is placed in after packing in -80 DEG C of ultra low temperature freezers.According to ELISA kit specification, histamine in serum is detected
Content.
As shown in Figure 2, compared with blank group, the content pole of histamine is significantly higher than blank group in model group, show modeling at
Work(；Compared with model group, histamine content significantly reduces each administration group；Of the present invention group of more pungent a kind of reed mentioned in ancient books side's group is for group in allergic rhinitis
The content of amine reduces advantageous.
6) guinea-pig nasal mucosal morphology is observed
After gastric infusion, by 10% chloral hydrate anesthesia of cavy, upper jaw osseous part skin is divested and by maxilla
The separate out from skull, along nose midline incision, the preceding stage casing of nasal septum is cut, is taken in nose by exposure nasal septum and bilateral nasal cavity
Nasal mucosal tissue every both sides is fixed in 10% paraformaldehyde, paraffin embedding, slice, HE dyeing, and micro- sem observation nose is viscous
The form of film.
The form of schneiderian membrane shows model group compared with blank group in Fig. 3, can be observed have a large amount of acidophilus in schneiderian membrane
Property granulocyte infiltration (arrow signified)；Each administration group is compared with model group, and eosinophil is than nose model group in schneiderian membrane
It is few, and schneiderian membrane form is better than model group；Of the present invention group with the infiltration of pungent a kind of reed mentioned in ancient books side's group eosinophil from schneiderian membrane
Situation and the more equal no significant difference of form.
Technical scheme of the present invention is being reduced from the safety of Chinese medicine compound prescription and allergic rhinitis disease itself feature
While genotoxic potential flavour of a drug asarum, and from sniffle (grabbing nose, sneezing, runny nose), schneiderian membrane morphology and induce allergic effect
Property rhinitis the aspect of main effects substance histamine content three illustrate technical scheme of the present invention in terms of the treatment of allergic rhinitis
The advantageous effect of acquirement：For symptom improvement, the alleviation of allergic rhinitis symptom is better than pungent a kind of reed mentioned in ancient books side's group；From schneiderian membrane form
Observation is learned, our group suitable with pungent a kind of reed mentioned in ancient books side's group to the reparation of schneiderian membrane after allergic rhinitis damage, and it is viscous to reduce nose simultaneously
The infiltration of film local inflammatory cells eosinophil etc.；The content that body histamine is reduced from drug says that our group to slightly excellent
Gesture.
Influence of the comprehensive drug to each leading indicator, show our group can be by reducing the content of effector substance histamine
Improve sniffle, reduce eosinophils and then reduce local inflammation, schneiderian membrane makes body be formed after repairing damage
Strong barrier is finally reached the treatment to allergic rhinitis to prevent the further deterioration of the state of an illness.
Amount of excipient ratio is 30%, and the hardness of tablet, disintegration time limited meet the requirements.
In tablet moulding process, the dosage of each excipient by weight percentage：Filler microcrystalline cellulose 20%, collapses
Solve agent carboxymethyl sodium starch 6%, adhesive povidone 3%, glidant magnesium stearate 1%.
The tablet prepared according to the method described above, every weight 0.6g, three times a day, 5 tablets once, 20 days as a treatment course.According to
Final screening combination, it is as shown in the table for three batches of experimental results：
Note：Fig. 4 is the discriminating collection of illustrative plates of scutelloside, angelica root and Astragaloside IV in sample.
Three batches the experimental results showed that the reproducibility stability of the moulding process of tablet meets formulation requirements.
The tablet hygroscopicity prepared is strong, and in order to keep tablet more stable, film coating is carried out to tablet.Prepared by the present invention
Tablet passes through to different solid contents (15%, 20%, 25%)Amb is screened, it is determined that final art for coating
ForAmb solid contents are 20%, and 40 DEG C, rotating speed 35rpm of piece bed tempertaure, coating weight gain is less than 4%, Coating times 55
~65min.
The thin membrane coated tablet prepared according to the technique is compared with plain piece, its hygroscopicity significantly drops under the conditions of different humidity
Low, it is as shown in the table for result：
With immediate prior art ratio, excellent effect of the invention is：
1) Chinese prescription provided by the invention reduces genotoxic potential flavour of a drug asarum on the basis of traditional Chinese medicine compound
Meanwhile and treatment to disease can be reached.Its potential side effect is reduced while reducing cost, it is intended to make Chinese medicine compound prescription more can be wide
General and safe is applied to clinic.
2) Chinese medicinal tablet provided by the invention is coated it using moistureproof coating liquid, overcomes Chinese medical concrete tablet moisture absorption
Property strong, unstable quality the shortcomings that, compared with plain piece, significantly reduce its hydroscopicity；And it is simple for process, save the time and at
This.
Description of the drawings
Fig. 1：Cavy administration before and after grab nose number (n=7) (administration before model group compared with blank group,***P < 0.001；It gives
Model group is compared with blank group after medicine,###P < 0.001；Each administration group compared with model group,△△△P < 0.001)
Fig. 2：Different pharmaceutical to histamine content in guinea pig serum influence (n=7) (model group compared with blank group,***P <
0.001；Each administration group compared with model group,△P < 0.05,△△△P < 0.001)
Fig. 3：Guinea-pig nasal mucosal morphology
Fig. 4：The discriminating collection of illustrative plates of scutelloside, angelica root and Astragaloside IV in sample
Specific implementation mode
Embodiment 1
Radix scutellariae, Radix Astragali, schizonepeta, the root of Dahurain angelica, the achene of Siberian cocklebur, cassia twig, grass-leaved sweetflag, Rhizoma Atractylodis Macrocephalae and windproof each 240g are weighed respectively, are added
10 times of amount water, decoct twice, 1.5 hours for the first time, second 1 hour, merge decoction liquor, and it is 1.1~1.2 to be concentrated into density,
Vacuum drying, obtains the active ingredient extract powder in preparation.The extract powder 420g that will be obtained, microcrystalline cellulose sodium 120g, carboxylic first
6g magnesium stearate mixings are added in base sodium starch 36g, povidone 18g, appropriate 90% alcohol granulation, and tabletting obtains 1000
Medicine.
Embodiment 2
Medicinal extract active ingredient is prepared by the identical method of embodiment 1,100 tablets of tablets are prepared according to following prescription：Medicinal extract
Powder 42g, microcrystalline cellulose 12g, sodium carboxymethyl starch 3.6g, sodium carboxymethylcellulose 1.8g, appropriate 90% alcohol granulation,
0.6g magnesium stearates.
Embodiment 3
Medicinal extract active ingredient is prepared by the same procedure of embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, starch 12g, sodium carboxymethyl starch 3.6g, sodium carboxymethylcellulose 1.8g, appropriate 90% alcohol granulation, 0.6g stearic acid
Magnesium.
Embodiment 4
Medicinal extract active ingredient is prepared by the identical method of embodiment 1,100 tablets of tablets are prepared according to following prescription：Medicinal extract
Powder 42g, pregelatinized starch 12g, sodium carboxymethyl starch 3.6g, sodium carboxymethylcellulose 1.8g, appropriate 90% alcohol granulation,
0.6g magnesium stearates.
Embodiment 5
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, crospovidone 3.6g, sodium carboxymethylcellulose 1.8g, appropriate 90% alcohol granulation, 0.6g are hard
Fatty acid magnesium.
Embodiment 6
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, low-substituted hydroxypropyl cellulose 3.6g, sodium carboxymethylcellulose 1.8g, appropriate 90% ethyl alcohol system
Grain, 0.6g magnesium stearates.
Embodiment 7
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, sodium carboxymethyl starch 3.6g, povidone 1.8g, appropriate 90% alcohol granulation, 0.6g stearic acid
Magnesium.
Embodiment 8
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, sodium carboxymethyl starch 3.6g, hydroxypropyl cellulose 1.8g, appropriate 90% alcohol granulation, 0.6g are hard
Fatty acid magnesium.
Embodiment 9
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, sodium carboxymethyl starch 3.6g, hydroxypropyl cellulose 1.8g, appropriate 90% alcohol granulation, 0.6g micro mists
Silica gel.
Embodiment 10
Medicinal extract active ingredient is prepared according to the method for embodiment 1,100 tablets of tablets are prepared according to following prescription：Extract powder
42g, microcrystalline cellulose 12g, sodium carboxymethyl starch 3.6g, hydroxypropyl cellulose 1.8g, appropriate 90% alcohol granulation, 0.6g are slided
Mountain flour.
Embodiment 11
The plain piece prepared 100 withAmb is moistureproof coating auxiliary material, and coating fluid solid content is 15%, piece bed temperature
40 DEG C of degree, rotating speed 35rpm is coated using conventional coating technology, obtains thin membrane coated tablet.
Embodiment 12
The plain piece prepared 100 withAmb is moistureproof coating auxiliary material, and coating fluid solid content is 20%, piece bed temperature
40 DEG C of degree, rotating speed 35rpm is coated using conventional coating technology, obtains thin membrane coated tablet.
Embodiment 13
The plain piece prepared 100 withAmb is moistureproof coating auxiliary material, and coating fluid solid content is 25%, piece bed temperature
40 DEG C of degree, rotating speed 35rpm is coated using conventional coating technology, obtains thin membrane coated tablet.
Embodiment 14
The plain piece prepared 1000 withAmb is moistureproof coating auxiliary material, and coating fluid solid content is 20%, piece bed
40 DEG C of temperature, rotating speed 35rpm are coated using conventional coating technology, obtain thin membrane coated tablet.
Finally it should be noted that：Described embodiment is only some embodiments of the present application, rather than all.It is based on
Embodiment in the application, it is obtained by those of ordinary skill in the art without making creative efforts every other
Embodiment is all being applied within pending claims hereof protection domain.
Claims (8)
1. a kind of tablet for treating allergic rhinitis, it is characterised in that be by weight percent meter 70% active ingredient and
30% excipient composition；The active ingredient be the radix scutellariae of equivalent, Radix Astragali, schizonepeta, the root of Dahurain angelica, the achene of Siberian cocklebur, cassia twig, grass-leaved sweetflag,
The water extract of Rhizoma Atractylodis Macrocephalae and windproof nine tastes medicinal material；The excipient include the filler medically received, disintegrant, adhesive,
Glidant and coating auxiliary material.
2. the tablet for the treatment of allergic rhinitis according to claim 1, it is characterised in that the filler is microcrystalline cellulose
One or more of element, starch and pregelatinized starch；The disintegrant is sodium carboxymethyl starch, crospovidone and low substitution
One or more of hypromellose；Described adhesive is that sodium carboxymethylcellulose, povidone and hydroxypropyl methyl are fine
Tie up one or more of element；The glidant is one or more of magnesium stearate, superfine silica gel powder and talcum powder；The packet
Clothing auxiliary material be hydroxypropyl methyl cellulose, Utech E100, Utech EPO andOne or more of amb.
3. the tablet for the treatment of allergic rhinitis according to claim 1, which is characterized in that the filler accounts for sheet weight
10~25%, the disintegrant accounts for the 4~8% of sheet weight, and described adhesive accounts for the 2~6% of sheet weight, and the glidant accounts for piece
The 0.5~1% of weight.
4. the tablet for the treatment of allergic rhinitis according to claim 3, which is characterized in that the filler is sheet weight
20%, the disintegrant is the 6% of sheet weight, and described adhesive is the 3% of sheet weight, and the glidant is the 1% of sheet weight.
5. a kind of preparation method for treating allergic rhinitis tablet, which is characterized in that the tablet is by weight percent meter
70% active ingredient and 30% excipient composition；The active ingredient is the radix scutellariae of equivalent, Radix Astragali, schizonepeta, the root of Dahurain angelica, Siberian cocklebur
The water extract of son, cassia twig, grass-leaved sweetflag, Rhizoma Atractylodis Macrocephalae and windproof nine tastes medicinal material；
The excipient includes the filler medically received, disintegrant, adhesive, glidant and coating auxiliary material；Will effectively at
The extract powder divided and filler, disintegrant, adhesive mixed pelletization, are added glidant tabletting, then be coated, obtain the Compound Tablet
Agent.
6. the preparation method for the treatment of allergic rhinitis tablet according to claim 5, which is characterized in that the active ingredient
The preparation method of extract powder is：Equivalent medicinal material is taken, 10 times of amount water are added, decoct twice, 1.5 hours for the first time, 1 is small for the second time
When, it is concentrated to give the active ingredient water extract that relative density is 1.1~1.2, it is dry, obtain the active ingredient extract powder.
7. the preparation method for the treatment of allergic rhinitis tablet according to claim 6, which is characterized in that the active ingredient
The drying mode of water extract be constant pressure and dry, be dried under reduced pressure and be spray-dried in one kind.
8. the preparation method for the treatment of allergic rhinitis tablet according to claim 7, the active ingredient water extract
Drying means：Constant pressure and dry at 60~80 DEG C；It is dried under reduced pressure at a temperature of 5~8Kpa pressure and 50~60 DEG C；Spray drying into
Air temperature is 120~140 DEG C, and leaving air temp is 70~80 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510069987.7A CN104547357B (en) | 2015-02-10 | 2015-02-10 | A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510069987.7A CN104547357B (en) | 2015-02-10 | 2015-02-10 | A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104547357A CN104547357A (en) | 2015-04-29 |
| CN104547357B true CN104547357B (en) | 2018-10-26 |
Family
ID=53065128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510069987.7A Expired - Fee Related CN104547357B (en) | 2015-02-10 | 2015-02-10 | A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547357B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672703A (en) * | 2004-03-23 | 2005-09-28 | 胡小兵 | Medicine xinqin tablet for treating allergic rhintis and its prepn |
| CN1958023A (en) * | 2005-10-31 | 2007-05-09 | 天津市润拓生物技术有限公司 | Animal use compound medicament with effects for invigorating qi, strengthening the superficial, dispelling wind-evil, and being sensible, and preparation method |
-
2015
- 2015-02-10 CN CN201510069987.7A patent/CN104547357B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672703A (en) * | 2004-03-23 | 2005-09-28 | 胡小兵 | Medicine xinqin tablet for treating allergic rhintis and its prepn |
| CN1958023A (en) * | 2005-10-31 | 2007-05-09 | 天津市润拓生物技术有限公司 | Animal use compound medicament with effects for invigorating qi, strengthening the superficial, dispelling wind-evil, and being sensible, and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 辛芩片对豚鼠鼻超敏反应的影响;张蓉等;《中国中药杂志》;20050531;第30卷(第10期);第785-788页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104547357A (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011000150A1 (en) | A medicinal composition for the treatment of bronchitis and preparation thereof | |
| WO2012027882A1 (en) | Pharmaceutical composition for treating insomnia and preparation method thereof | |
| CN101564459A (en) | Application of Chinese medicinal composition in preparing medicament for treating upper respiratory tract infection | |
| CN101366876A (en) | Traditional Chinese medicine preparation for treating throat irritation and preparation method thereof | |
| CN107648468B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof | |
| CN101618146A (en) | Complex traditional Chinese medicine preparation for treating upper respiratory tract infection and preparation method thereof | |
| CN106729140B (en) | Compound preparation for treating influenza and preparation method thereof | |
| CN104547357B (en) | A kind of Chinese medicine compound prescription that treating allergic rhinitis, tablet and preparation method thereof | |
| CN109820947A (en) | A kind of application of Chinese medicine composition in preparation treatment epithelium healing cough syndrome drug | |
| CN104225196A (en) | Traditional Chinese medicine effervescent tablet for treating respiratory diseases and preparation method of traditional Chinese medicine effervescent tablet | |
| CN101199745A (en) | Medicament for treating cough | |
| CN100430085C (en) | Medicine for ventilating the lung and resolving phlegm to relieve cough and preparing method | |
| CN114712478A (en) | Traditional Chinese medicine composition and preparation for treating intestinal diseases and preparation method thereof | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN107753567B (en) | Anti-fatigue pharmaceutical composition and preparation method and application thereof | |
| CN100398097C (en) | Siji sanhuang new preparation and preparing method and application | |
| CN107669764A (en) | Pharmaceutical composition of combination therapy of Chinese and western bronchitis and preparation method thereof | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN115708859B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN111686085B (en) | Preparation method of throat clearing preparation | |
| CN108653554B (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN106924529A (en) | A kind of Chinese medicine composition for treating cough, containing its preparation and preparation method and application | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN1951494B (en) | Compound Chinese medicinal preparation for treating affection of external wind and cold and preparation method thereof | |
| CN107582778B (en) | Traditional Chinese medicine composition for treating throat diseases, pharmaceutical preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181026 Termination date: 20210210 |